巴曲酶治疗中度以上突发性耳聋的疗效观察

发布时间：2018-01-04 11:27

本文关键词：巴曲酶治疗中度以上突发性耳聋的疗效观察　出处：《重庆医学》2015年16期 　论文类型：期刊论文

【摘要】：目的了解巴曲酶治疗中度以上突发性聋(简称突聋)的疗效和预后影响因素,以更好地进行临床治疗。方法回顾性分析2010年10月至2011年10月在该院就诊的56例(共57耳)中度以上平坦型(22耳)和全聋型突聋(35耳)患者的临床资料。其中有33耳常规用药治疗(常规用药组),24耳在常规用药基础上联合应用了巴曲酶治疗(联合组)。结果联合组(66.7%)和常规用药组(33.3%)治疗中度以上突聋患者的总有效率差异有统计学意义(P=0.012 8)。平坦型与全聋型的总有效率差异有统计学意义(P=0.012 6)。结论常规用药联合巴曲酶能显著提高中度以上突聋患者的总有效率,疗效优于单用常规药物,且全聋型较平坦型预后差。
[Abstract]:Objective to investigate the efficacy and prognostic factors of batroxobin in the treatment of sudden and moderate deafness. Methods from October 2010 to October 2011, 56 cases (57 ears) with moderate or flat type deafness (n = 22) and deafness with sudden deafness (n = 22) were analyzed retrospectively. Clinical data of 35 ears. 33 ears were treated with routine medicine (routine medication group). 24 ears were treated with batroxobin on the basis of routine medicine. Results the combined group was 66.7% and the routine group was 33.3%. The difference of total effective rate in patients with moderate or severe sudden deafness was statistically significant (P 0.0128), and there was significant difference between flat type and total deafness type (P 0.0126). Conclusion routine medication combined with batroxobin can significantly improve the total effective rate of patients with moderate or sudden deafness. The curative effect was better than that of routine medicine alone, and the prognosis of total deafness type was worse than that of flat type.
【作者单位】：重庆医科大学附属第一医院健康体检部;重庆医科大学附属第一医院耳鼻咽喉科;
【基金】：国家临床重点专科建设项目(卫办医政函[2012]649号)
【分类号】：R764.437
【正文快照】： 突发性耳聋(以下简称突聋)是耳科常见的急症,近年来发病率有增加和年轻化趋势。虽然突聋有一定的自愈率,但是对于中度以上的听力损失不能自行恢复,需要积极治疗,否则遗留永久性听力损失,影响生活和工作。中国济南指南[1]和德国指南[2]主张使用溶栓治疗,但美国指南[3]不推荐常

【参考文献】